Insider Selling: Liquidia (NASDAQ:LQDA) CFO Sells 1,166 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) CFO Michael Kaseta sold 1,166 shares of the firm’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $32.19, for a total value of $37,533.54. Following the transaction, the chief financial officer directly owned 353,823 shares of the company’s stock, valued at $11,389,562.37. This represents a 0.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Michael Kaseta also recently made the following trade(s):

• On Monday, October 13th, Michael Kaseta sold 11,630 shares of Liquidia stock. The stock was sold at an average price of $23.41, for a total value of $272,258.30.

Liquidia Stock Performance

NASDAQ:LQDA traded down $1.26 during trading hours on Tuesday, reaching $30.79. The company had a trading volume of 1,614,836 shares, compared to its average volume of 2,006,737. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19. Liquidia Corporation has a 52 week low of $10.37 and a 52 week high of $32.80. The firm has a market cap of $2.68 billion, a price-to-earnings ratio of -21.38 and a beta of 0.48. The firm’s 50 day moving average price is $25.41 and its 200-day moving average price is $21.48.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.41. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The firm had revenue of $54.34 million during the quarter, compared to the consensus estimate of $18.86 million. The business’s revenue was up 1106.7% on a year-over-year basis. On average, analysts forecast that Liquidia Corporation will post -1.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LQDA. Raymond James Financial reissued a “strong-buy” rating and set a $47.00 target price on shares of Liquidia in a research report on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research note on Wednesday, October 8th. Jefferies Financial Group restated a “buy” rating and set a $45.00 target price on shares of Liquidia in a research report on Monday, November 3rd. BTIG Research restated a “buy” rating and set a $49.00 target price on shares of Liquidia in a research report on Tuesday, November 4th. Finally, Wells Fargo & Company initiated coverage on Liquidia in a research report on Monday, October 20th. They issued an “overweight” rating and a $31.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Liquidia presently has an average rating of “Moderate Buy” and an average price target of $38.56.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. NewEdge Advisors LLC acquired a new position in Liquidia in the 2nd quarter valued at about $25,000. Skandinaviska Enskilda Banken AB publ purchased a new stake in Liquidia during the third quarter valued at about $30,000. Steward Partners Investment Advisory LLC raised its holdings in Liquidia by 24.0% in the second quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock valued at $77,000 after buying an additional 1,200 shares during the period. Quarry LP acquired a new position in shares of Liquidia during the 1st quarter valued at $79,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Liquidia by 281.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after buying an additional 4,927 shares during the period. 64.54% of the stock is currently owned by institutional investors and hedge funds.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).